靶向蛋白质降解 (TPD) 治疗的新兴前景

快速的技术进步加强了强大的处理管道

Frost & Sullivan 的研究报告对新兴的靶向蛋白质降解 (TPD) 领域进行了深入分析。通过以受控方式攻击致病蛋白并降低副作用风险，TPD 策略使得治疗多种常规方法仍无法治疗的疾病成为可能。

据估计，80% 的细胞蛋白质组无法通过小分子抑製剂、ASO 和单克隆抗体等传统方法来靶向，从而导致了 TPD 方法的发展。事实上，TPD 在过去二十年中已经取得了长足的进步，PROTAC 已成为有史以来研究的最常见的蛋白水解酶。随着新技术的出现，已经开发了几种类型的蛋白水解剂。

主要有两种类型：细胞内降解剂和细胞外降解剂。迄今为止，细胞内蛋白水解剂已得到最广泛的研究。他们利用泛素蛋白酶体降解途径来降解细胞内蛋白质，但估计有 40% 的编码细胞外和膜相关蛋白的基因不能被细胞内蛋白水解剂靶向，这导致了细胞外蛋白水解剂的开发。

增加私人和公共资金是推动靶向蛋白质降解技术发展的关键因素。本报告包括对 TPD 行业融资趋势的分析。

本报告讨论了细胞外和细胞内蛋白水解剂的类型及其研发重点领域。我们还分析了不同降解物在不同疾病中的适用性，并确定其临床应用和相关关键参与者。最后，Frost & Sullivan 为 TPD 确定了四个可以改变市场的增长机会。

本报告试图回答的问题是：

• 1. TPD发展的主要促进因素和挑战是什么？
• 2. TPD 的私人资金和合作伙伴关係状况如何？
• 3.开发靶向蛋白酶的主要行业相关人员有哪些？
• 4. TPD的研发趋势有哪些可能促进蛋白水解酶的开发？

目录

战略问题

• 为什么成长如此困难？
• The Strategic Imperative 8 (TM)
• 靶向蛋白水解行业的战略问题：三大影响
• 通过增长机会加速增长管道引擎 (TM)
• 调查方法
• 介绍

增长机会分析

• 增长促进因素
• 促进因素分析
• 生长抑制因素
• 生长抑制因素分析
• 分析范围
• 分割
• 需要靶向蛋白水解剂

研发与创新生态系统

• TPD 的演变和临床方面
• 细胞内靶向蛋白水解药物的临床开发
• 细胞内靶向蛋白水解剂：PROTAC
• 新型细胞内靶向蛋白水解药物
• 创新焦点：细胞内蛋白质降解
• 细胞外蛋白水解药物的开发
• 细胞外蛋白水解治疗剂开发中的问题
• 细胞外蛋白水解方法
• 一类新型细胞外蛋白水解剂
• 创新焦点：细胞外蛋白质降解
• 细胞外和细胞内蛋白质靶标之间的主要区别
• 靶向蛋白水解：技术概览

研发重点及应用前景

• 研发与创新趋势
• 医学及其他领域的蛋白质降解
• 各种疾病领域的蛋白水解剂
• 各大公司及热点治疗领域
• 蛋白水解剂的创新前景

市场动态

• TPD 药物开发的公共和私人资金
• 生物製药公司在TPD药物开发中的合作状况
• TPD 公司合作开发 TPD 疗法

充满增长机会的宇宙

• 增长机会 1：降解物的高效和组织特异性递送
• 增长机会2：新型E3连接酶的发现和设计
• 成长机会3：先进PROTAC的开发
• 增长机会4：研发合作开发下一代TPD药物

附录

• 附录
• 附录

下一步

• 下一步
• 为什么选择 Frost & Sullivan，为什么现在
• 免责声明

Rapid Technology Advances Bolster a Robust Therapeutic Pipeline

This Frost & Sullivan research report provides an in-depth analysis of the emerging targeted protein degradation (TPD) space. TPD strategies enable treating various diseases not yet treatable via conventional approaches by attacking disease-causing proteins in a controlled manner, thus reducing the risk of side effects.

It is estimated that 80% of a cell's proteome cannot be targeted via traditional approaches such as small molecule inhibitors, ASO, or monoclonal antibodies, which has led to the development of TPD approaches. Indeed, TPD has advanced enormously in the last two decades, and PROTACs have emerged as the most common protein degrader researched until now. As new technologies emerge, several types of protein degraders have been developed.

Two main types exist: intracellular and extracellular degraders. Until now, intracellular protein degraders have been the most extensively studied. These degrade intracellular proteins by leveraging the ubiquitin-proteasomal degradation pathway, but an estimated 40% of genes encoding extracellular and membrane-associated proteins cannot be targeted by intracellular protein degraders, leading to the development of extracellular protein degradation.

Increased private and public funding is an important factor driving the growth of targeted protein degradation technology. This report includes an analysis of funding trends in the TPD space.

This report discusses the different types of extracellular and intracellular protein degraders and R&D focus areas; it analyses the applicability of different degraders across various diseases and identifies their clinical translation and related key players. Finally, Frost & Sullivan has identified four growth opportunities for TPD that could potentially transform the market.

Questions that this report seeks to answer include:

• 1. What are the key drivers or challenges for TPD development?

• 2. How do the private funding and partnership landscapes look for TPD?

• 3. Who are the key industry participants developing targeted protein degraders?

• 4. What are the R&D trends emerging across TPD that could further shape the development of protein degraders?

Table of Contents

Strategic Imperatives

• Why Is It Increasingly Difficult to Grow?
• The Strategic Imperative 8™
• The Impact of the Top 3 Strategic Imperatives on the Targeted Protein Degradation Industry
• Growth Opportunities Fuel the Growth Pipeline Engine™
• Research Methodology
• Introduction

Growth Opportunity Analysis

• Growth Drivers
• Growth Driver Analysis
• Growth Restraints
• Growth Restraints Analysis
• Scope of Analysis
• Segmentation
• The Need for Targeted Protein Degraders

R&D and Innovation Ecosystem

• TPD-Evolution and Clinical aspect
• Intracellular Targeted Protein Degraders in Clinical Development
• Intracellular Targeted Protein Degraders-PROTACs
• Emerging Intracellular Targeted Protein Degraders
• Innovation Spotlight-Intracellular Protein Degradation
• Development of Extracellular Protein Degradation Therapeutics
• Challenges for Extracellular Protein Degrader Development
• Extracellular Protein Degradation Approaches
• Emerging Classes of Extracellular Protein Degraders
• Innovation Spotlight-Extracellular Protein Degradation
• Key Differences Between Extracellular and Intracellular Protein Targeting
• Targeted Protein Degradation Technology Snapshot

R&D Focus and Application Landscape

• R&D Innovation Trends
• Protein Degraders in Healthcare and Beyond
• Protein Degraders across Different Disease Areas
• Key Players and Therapeutics Areas of Focus
• Protein Degraders Innovation Landscape

Market Dynamics

• Public and Private Funding for TPD Therapy Development
• Partnership Landscape of Biopharma Companies in TPD Therapeutics Development
• TPD Companies' Partnerships for Developing TPD Therapeutics

Growth Opportunity Universe

• Growth Opportunity 1: Efficient and Tissue-specific Degrader Delivery
• Growth Opportunity 2: Novel E3 Ligases Discovery and Design
• Growth Opportunity 3: Advanced PROTACs Development
• Growth Opportunity 4: Research and Product Development Partnerships to Develop Next-gen TPD Therapeutics

Appendix

• Appendix
• Appendix

Next Steps

• Your Next Steps
• Why Frost, Why Now?
• Legal Disclaimer